Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daywin Patel

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Cardiovascular Toxicology|June 29, 2018
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted DrugsBrian B Hasinoff, Daywin Patel
Journal of Inorganic Biochemistry|June 19, 2009
The iron chelator Dp44mT does not protect myocytes against doxorubicinBrian B Hasinoff, Daywin Patel
Cardiovascular Toxicology|March 4, 2020
Mechanisms of the Cardiac Myocyte-Damaging Effects of DasatinibBrian B Hasinoff, Daywin Patel
Archives of Biochemistry and Biophysics|September 10, 2017
Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activityBrian B Hasinoff, Daywin Patel
Cardiovascular Toxicology|November 17, 2009
Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenibBrian B Hasinoff, Daywin Patel
Toxicology and Applied Pharmacology|September 14, 2010
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitroBrian B Hasinoff, Daywin Patel
Free Radical Biology & Medicine|December 4, 2003
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicinBrian B Hasinoff, Daywin Patel, Xing Wu
Journal of Inorganic Biochemistry|November 4, 2004
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycinXing Wu, Daywin Patel, Brian B Hasinoff
Cardiovascular Toxicology|July 25, 2007
The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independentBrian B Hasinoff, Daywin Patel, Xing Wu
Toxicology and Applied Pharmacology|May 18, 2020
A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibitionBrian B Hasinoff, Daywin Patel, Xing Wu
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Cardiovascular Toxicology|June 29, 2018
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted DrugsBrian B Hasinoff, Daywin Patel
Journal of Inorganic Biochemistry|June 19, 2009
The iron chelator Dp44mT does not protect myocytes against doxorubicinBrian B Hasinoff, Daywin Patel
Cardiovascular Toxicology|March 4, 2020
Mechanisms of the Cardiac Myocyte-Damaging Effects of DasatinibBrian B Hasinoff, Daywin Patel
Archives of Biochemistry and Biophysics|September 10, 2017
Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activityBrian B Hasinoff, Daywin Patel
Cardiovascular Toxicology|November 17, 2009
Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenibBrian B Hasinoff, Daywin Patel
Toxicology and Applied Pharmacology|September 14, 2010
The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitroBrian B Hasinoff, Daywin Patel
Free Radical Biology & Medicine|December 4, 2003
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicinBrian B Hasinoff, Daywin Patel, Xing Wu
Journal of Inorganic Biochemistry|November 4, 2004
The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycinXing Wu, Daywin Patel, Brian B Hasinoff
Cardiovascular Toxicology|July 25, 2007
The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independentBrian B Hasinoff, Daywin Patel, Xing Wu
Toxicology and Applied Pharmacology|May 18, 2020
A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibitionBrian B Hasinoff, Daywin Patel, Xing Wu
Pageof 5